New hope for immunotherapy as prostate cancer treatment
Combining PIM1 kinase inhibition with immune checkpoint inhibitors sensitizes prostate tumors to immunotherapy, reducing tumor growth in preclinical models.
In vitro and animal studies demonstrate that inhibition of PIM1 kinase in tumor‑associated macrophages enhances the efficacy of immune checkpoint inhibitors, leading to reduced tumor growth in prostate cancer.
Prostate cancer has been largely resistant to immune checkpoint inhibitors; this new strategy may unlock effective immunotherapy for a disease with limited treatment options and could inform future clinical trials.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience